Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
作者信息
Blauvelt Andrew, Garrelts Alyssa, Malatestinic William, Birt Julie, Zhu Baojin, Feely Meghan
机构信息
Oregon Medical Research Center, Portland, OR, USA.
Eli Lilly and Company, Indianapolis, IN, USA.
出版信息
Dermatol Ther (Heidelb). 2023 Nov;13(11):2911-2916. doi: 10.1007/s13555-023-01015-w. Epub 2023 Sep 26.
Abstract
摘要
相似文献
1
Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
Dermatol Ther (Heidelb). 2023 Nov;13(11):2911-2916. doi: 10.1007/s13555-023-01015-w. Epub 2023 Sep 26.
2
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
Dermatol Ther (Heidelb). 2023 Apr;13(4):1053-1068. doi: 10.1007/s13555-023-00910-6. Epub 2023 Mar 16.
3
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
JAMA Dermatol. 2022 Oct 1;158(10):1131-1141. doi: 10.1001/jamadermatol.2022.2909.
4
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
Dermatol Ther (Heidelb). 2023 Nov;13(11):2917-2923. doi: 10.1007/s13555-023-01017-8. Epub 2023 Sep 26.
5
Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study.
Clin Cosmet Investig Dermatol. 2022 Oct 20;15:2245-2252. doi: 10.2147/CCID.S387759. eCollection 2022.
6
A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
Dermatol Ther (Heidelb). 2022 Mar;12(3):701-714. doi: 10.1007/s13555-022-00686-1. Epub 2022 Feb 26.
7
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Am J Clin Dermatol. 2022 Nov;23(6):891-904. doi: 10.1007/s40257-022-00722-y. Epub 2022 Aug 17.
8
The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
Dermatol Ther (Heidelb). 2017 Dec;7(4):425-446. doi: 10.1007/s13555-017-0207-0. Epub 2017 Nov 15.
9
Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population-Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database.
Dermatol Ther (Heidelb). 2022 Mar;12(3):741-752. doi: 10.1007/s13555-022-00691-4. Epub 2022 Feb 24.
10
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Lancet. 2019 Sep 7;394(10201):831-839. doi: 10.1016/S0140-6736(19)31773-8. Epub 2019 Aug 8.
引用本文的文献
1
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
Dermatol Ther (Heidelb). 2023 Nov;13(11):2917-2923. doi: 10.1007/s13555-023-01017-8. Epub 2023 Sep 26.
本文引用的文献
1
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
Dermatol Ther (Heidelb). 2023 Apr;13(4):1053-1068. doi: 10.1007/s13555-023-00910-6. Epub 2023 Mar 16.
2
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2087-2100. doi: 10.1111/jdv.18376. Epub 2022 Jul 29.
3
Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
JAMA Dermatol. 2022 May 1;158(5):513-522. doi: 10.1001/jamadermatol.2022.0364.
4
Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA.
Dermatol Ther (Heidelb). 2022 Apr;12(4):971-987. doi: 10.1007/s13555-022-00707-z. Epub 2022 Mar 19.
5
A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
Dermatol Ther (Heidelb). 2022 Mar;12(3):701-714. doi: 10.1007/s13555-022-00686-1. Epub 2022 Feb 26.
6
Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
Dermatology. 2022;238(3):438-447. doi: 10.1159/000519176. Epub 2021 Oct 28.
7
Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study.
Dermatol Ther (Heidelb). 2021 Dec;11(6):2107-2121. doi: 10.1007/s13555-021-00616-7. Epub 2021 Oct 14.
8
Assessing Heterogeneity of Treatment Effects in Observational Studies.
Am J Epidemiol. 2021 Jun 1;190(6):1088-1100. doi: 10.1093/aje/kwaa235.
9
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Br J Dermatol. 2020 Aug;183(2):294-302. doi: 10.1111/bjd.18981. Epub 2020 Mar 30.
10
Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population.
J Dermatolog Treat. 2021 Sep;32(6):595-602. doi: 10.1080/09546634.2019.1687828. Epub 2020 Jan 8.
Zotero 插件